Svmuu News Venus Protocol has issued a statement regarding the THE market incident, clarifying that it was not a flash loan attack but rather the result of an attacker exploiting a supply cap execution vulnerability in the protocol's legacy code. The team stated that the attacker had been accumulating THE tokens over approximately nine months, gradually establishing a dominant supply position on Venus.
The announcement pointed out that the attacker bypassed the normal deposit process by directly transferring THE tokens into the protocol contract, thereby breaking through the 14.5 million THE supply cap limit. They then manipulated DEX prices by taking advantage of the low on-chain liquidity. As the external price was gradually reflected by the TWAP oracle, the attacker cyclically borrowed assets (such as CAKE, BNB, etc.) using the inflated collateral value, bought more THE to push the price higher, and continuously transferred THE into the vTHE market to increase the collateral value. This cycle drove the price from around $0.27 to approximately $0.53, ultimately leaving bad debt in the protocol after the position was liquidated.
Venus stated that it has currently suspended the THE market, reducing its collateral factor to 0 and pausing withdrawals. Additionally, as a precautionary measure, the collateral factors for eight other markets—BCH, LTC, AAVE, POL, FIL, TWT, UNI, and lisUSD—have also been reduced to 0. The team and security partners are continuing their investigation and will release a comprehensive post-mortem analysis report subsequently.
Venus Protocol: THE Market Incident Stemmed from Supply Cap Vulnerability, Not a Flash Loan Attack
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
2
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
3
Analysis Compares Healthcare ETFs: Invesco Nasdaq Biotech ETF (IBBQ) Saw 45.5% One-Year Return, Outperforming State Street Healthcare Select Sector SPDR ETF (XLV)
-
4
Iran-linked exchange Shelbit allegedly sent $676 million to Binance in sanctions-evasion operation, Reuters reports
-
5
Analysis: Vanguard Small-Cap Growth ETF (VBK) up 21% YTD 2026, Outperforming Large-Cap Growth ETF (VONG) at 0.3% YTD
-
6
Berkshire Hathaway Holds Record $400B Cash, Net Seller for 3+ Years; "Buffett Indicator" Hits All-Time High Suggesting Stocks Are Expensive
-
7
What Is POLA? Background and Investment Risk Analysis of the Pola On Base Project
-
8
Claiming Social Security benefits at age 62 instead of 67 can reduce monthly payments by 30%, potentially costing average retirees $150,000 over 20 years.
-
9
What Is DuckChain (DUCK)? An Analysis of Its Future Prospects
-
10
Analysis: Roundhill N-100 0DTE Covered Call ETF (QDTE) Payouts May Include Return of Capital, Trailing Nasdaq-100 Performance
Markets Today
Recommended Reading





